CA2960777A1 - Macrocyclic lrrk2 kinase inhibitors - Google Patents
Macrocyclic lrrk2 kinase inhibitors Download PDFInfo
- Publication number
- CA2960777A1 CA2960777A1 CA2960777A CA2960777A CA2960777A1 CA 2960777 A1 CA2960777 A1 CA 2960777A1 CA 2960777 A CA2960777 A CA 2960777A CA 2960777 A CA2960777 A CA 2960777A CA 2960777 A1 CA2960777 A1 CA 2960777A1
- Authority
- CA
- Canada
- Prior art keywords
- 6alkyl
- halo
- 6a1ky1
- optionally
- independently substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 C*1NCC(*)*NC(*)CC1 Chemical compound C*1NCC(*)*NC(*)CC1 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14290279.0 | 2014-09-17 | ||
| EP14290279 | 2014-09-17 | ||
| PCT/EP2015/071349 WO2016042089A1 (en) | 2014-09-17 | 2015-09-17 | Macrocyclic lrrk2 kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2960777A1 true CA2960777A1 (en) | 2016-03-24 |
Family
ID=51752058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2960777A Abandoned CA2960777A1 (en) | 2014-09-17 | 2015-09-17 | Macrocyclic lrrk2 kinase inhibitors |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10377772B2 (enExample) |
| EP (1) | EP3194405B1 (enExample) |
| JP (1) | JP2017529365A (enExample) |
| KR (1) | KR20170048599A (enExample) |
| CN (1) | CN107108641A (enExample) |
| AU (1) | AU2015316801B2 (enExample) |
| BR (1) | BR112017005299A2 (enExample) |
| CA (1) | CA2960777A1 (enExample) |
| DK (1) | DK3194405T3 (enExample) |
| EA (1) | EA032838B1 (enExample) |
| ES (1) | ES2717510T3 (enExample) |
| HU (1) | HUE043972T2 (enExample) |
| IL (1) | IL251054B (enExample) |
| MX (1) | MX2017003470A (enExample) |
| PL (1) | PL3194405T4 (enExample) |
| SG (1) | SG11201701936WA (enExample) |
| TR (1) | TR201904514T4 (enExample) |
| TW (1) | TW201625639A (enExample) |
| WO (1) | WO2016042089A1 (enExample) |
| ZA (1) | ZA201701841B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111221514B (zh) * | 2020-01-13 | 2023-03-03 | 陕西心像信息科技有限公司 | 基于OsgEarth的三维可视化组件实现方法及系统 |
| AR124556A1 (es) * | 2020-01-31 | 2023-04-12 | Oncodesign Sa | Inhibidores macrocíclicos de rip2-cinasa |
| CR20220561A (es) | 2020-05-06 | 2023-02-17 | Servier Lab | Nuevos inhibidores macrocíclicos de la quinasa de lrrk2 |
| MX2023010910A (es) | 2021-03-18 | 2023-09-27 | Servier Lab | Nuevos inhibidores macrociclicos de la quinasa de lrrk2. |
| WO2023064768A1 (en) * | 2021-10-11 | 2023-04-20 | Baylor College Of Medicine | G-protein-coupled receptor regulators and methods of use thereof |
| US11780851B2 (en) | 2021-10-27 | 2023-10-10 | H. Lundbeck A/S | LRRK2 inhibitors |
| CN117425660A (zh) * | 2022-05-18 | 2024-01-19 | 上海翊石医药科技有限公司 | 一种芳杂环类化合物及其中间体、药物组合物和用途 |
| AR130483A1 (es) | 2022-09-15 | 2024-12-11 | H Lundbeck As | Inhibidores de la cinasa con repeticiones ricas en leucina 2 (lrrk2) |
| AR132486A1 (es) * | 2023-04-20 | 2025-07-02 | H Lundbeck As | Inhibidores de la cinasa con repeticiones ricas en leucina 2 (lrrk2) |
| AR132487A1 (es) * | 2023-04-20 | 2025-07-02 | H Lundbeck As | Inhibidores de la cinasa con repeticiones ricas en leucina 2 (lrrk2) |
| AR132488A1 (es) * | 2023-04-20 | 2025-07-02 | H Lundbeck As | Inhibidores de la cinasa con repeticiones ricas en leucina 2 (lrrk2) |
| WO2024218296A1 (en) * | 2023-04-20 | 2024-10-24 | H. Lundbeck A/S | Combination treatments comprising administration of leucine-rich repeat kinase 2 (lrrk2) inhibitors |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IS2334B (is) | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
| RU2170082C2 (ru) | 1993-10-01 | 2001-07-10 | Астра Актиеболаг | Способ обработки лекарственного средства, устройство для формирования лекарственного средства и лекарственное средство |
| EP0729758A3 (en) | 1995-03-02 | 1997-10-29 | Pfizer | Pyrazolopyrimidines and pyrrolopyrimidines for the treatment of neuronal and other diseases |
| US6043358A (en) | 1995-11-01 | 2000-03-28 | Merck & Co., Inc. | Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases |
| HU228962B1 (en) | 1996-07-24 | 2013-07-29 | Bristol Myers Squibb Pharma Co | Azolo triazines, pharmaceutical compositions containing them and use of the compounds |
| GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| US6194410B1 (en) | 1998-03-11 | 2001-02-27 | Hoffman-La Roche Inc. | Pyrazolopyrimidine and pyrazolines and process for preparation thereof |
| US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| CN1274690C (zh) | 2000-12-28 | 2006-09-13 | 小野药品工业株式会社 | 三杂环化合物和包括其作为活性组分的药物 |
| US7067507B2 (en) * | 2001-06-12 | 2006-06-27 | Pharmacia & Upjohn Company | Macrocycles useful in the treatment of Alzheimer's disease |
| ES2393926T3 (es) | 2004-10-21 | 2013-01-02 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) | Gen KASPP (LRRK2), su producción y uso para la detección y tratamiento de trastornos neurodegenerativos |
| NO323175B1 (no) | 2004-12-23 | 2007-01-15 | Jan O Aasly | Framgangsmate for a pavise en mutasjon som forarsaker arvelig parkinsonisme |
| FI123725B (fi) | 2005-08-01 | 2013-10-15 | Reijo Viljanen | Menetelmä sahalaitteen terän jännittämiseksi ja ohjaamiseksi sekä ohjaus- ja jännityslaitteet |
| CN101365703B (zh) | 2005-11-16 | 2013-11-06 | S*Bio私人有限公司 | 杂烷基连接的嘧啶衍生物 |
| WO2009127642A2 (en) | 2008-04-15 | 2009-10-22 | Cellzome Limited | Use of lrrk2 inhibitors for neurodegenerative diseases |
| ES2512727T3 (es) | 2009-09-29 | 2014-10-24 | Glaxo Group Limited | Nuevos compuestos |
| SMT201700372T1 (it) * | 2010-05-20 | 2017-09-07 | Array Biopharma Inc | Composti macrociclici come inibitori di trk chinasi |
| WO2013001310A1 (en) * | 2011-06-30 | 2013-01-03 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Macrocyclic compounds and their use as cdk8 inhibitors |
| HUE027318T2 (en) * | 2011-09-30 | 2016-10-28 | Oncodesign Sa | Macrocyclic FLT3 kinase inhibitors |
| PL2760453T3 (pl) | 2011-09-30 | 2016-11-30 | Makrocykliczne Inhibitory kinazy LRRK2 |
-
2015
- 2015-09-17 TW TW104130753A patent/TW201625639A/zh unknown
- 2015-09-17 BR BR112017005299A patent/BR112017005299A2/pt not_active IP Right Cessation
- 2015-09-17 CN CN201580061216.1A patent/CN107108641A/zh active Pending
- 2015-09-17 EP EP15766801.3A patent/EP3194405B1/en not_active Not-in-force
- 2015-09-17 US US15/511,879 patent/US10377772B2/en not_active Expired - Fee Related
- 2015-09-17 MX MX2017003470A patent/MX2017003470A/es unknown
- 2015-09-17 AU AU2015316801A patent/AU2015316801B2/en not_active Ceased
- 2015-09-17 DK DK15766801.3T patent/DK3194405T3/en active
- 2015-09-17 SG SG11201701936WA patent/SG11201701936WA/en unknown
- 2015-09-17 KR KR1020177010322A patent/KR20170048599A/ko not_active Withdrawn
- 2015-09-17 JP JP2017515823A patent/JP2017529365A/ja active Pending
- 2015-09-17 WO PCT/EP2015/071349 patent/WO2016042089A1/en not_active Ceased
- 2015-09-17 HU HUE15766801A patent/HUE043972T2/hu unknown
- 2015-09-17 EA EA201790626A patent/EA032838B1/ru not_active IP Right Cessation
- 2015-09-17 CA CA2960777A patent/CA2960777A1/en not_active Abandoned
- 2015-09-17 PL PL15766801T patent/PL3194405T4/pl unknown
- 2015-09-17 ES ES15766801T patent/ES2717510T3/es active Active
- 2015-09-17 TR TR2019/04514T patent/TR201904514T4/tr unknown
-
2017
- 2017-03-09 IL IL251054A patent/IL251054B/en not_active IP Right Cessation
- 2017-03-15 ZA ZA2017/01841A patent/ZA201701841B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016042089A1 (en) | 2016-03-24 |
| HUE043972T2 (hu) | 2019-09-30 |
| PL3194405T3 (pl) | 2019-07-31 |
| MX2017003470A (es) | 2017-08-07 |
| DK3194405T3 (en) | 2019-04-15 |
| ES2717510T3 (es) | 2019-06-21 |
| AU2015316801B2 (en) | 2019-03-07 |
| EP3194405A1 (en) | 2017-07-26 |
| ZA201701841B (en) | 2019-08-28 |
| PL3194405T4 (pl) | 2019-07-31 |
| SG11201701936WA (en) | 2017-04-27 |
| JP2017529365A (ja) | 2017-10-05 |
| US20170240565A1 (en) | 2017-08-24 |
| EP3194405B1 (en) | 2018-12-26 |
| KR20170048599A (ko) | 2017-05-08 |
| AU2015316801A1 (en) | 2017-04-27 |
| EA201790626A1 (ru) | 2017-07-31 |
| TR201904514T4 (tr) | 2019-04-22 |
| IL251054A0 (en) | 2017-04-30 |
| IL251054B (en) | 2019-03-31 |
| BR112017005299A2 (pt) | 2017-12-12 |
| US10377772B2 (en) | 2019-08-13 |
| TW201625639A (zh) | 2016-07-16 |
| CN107108641A (zh) | 2017-08-29 |
| EA032838B1 (ru) | 2019-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2960777A1 (en) | Macrocyclic lrrk2 kinase inhibitors | |
| JP6082397B2 (ja) | マクロ環状ｌｒｒｋ２キナーゼ阻害剤 | |
| CA3121408A1 (en) | Heteroaromatic derivatives for use as regulator, preparation method therefor and use thereof | |
| DK2970333T3 (en) | MACROCYCLIC LRRK2 KINase INHIBITORS | |
| CA2868156C (en) | Substituted pyridopyrimidine compounds and their use as flt3 inhibitors | |
| EP3638680B1 (en) | Heteroaromatic compounds as vanin inhibitors | |
| AU2016322813A1 (en) | Novel imidazo (4,5-c) quinoline and imidazo (4,5-c)(1,5) naphthyridine derivatives as LRRK2 inhibitors | |
| CA2906262A1 (en) | Macrocyclic salt-inducible kinase inhibitors | |
| WO2014155300A2 (en) | Substitued pyrimidine amine derivatives as tak-1 inhibitors | |
| EP3481824B1 (en) | 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ror1 activity | |
| KR20200090636A (ko) | 피롤로피리미딘 유도체 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 | |
| CA2958782C (en) | Macrocyclic rip2 kinase inhibitors | |
| IL297767A (en) | Novel imidazolones as inhibitors of protein kinases in particular dyrk1a, clk1 and/or clk4 | |
| US11660303B2 (en) | 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity | |
| HK1240586A1 (zh) | 大环lrrk2激酶抑制剂 | |
| EP2968326A1 (en) | Macrocyclic salt-inducible kinase inhibitors | |
| HK1219481B (en) | Macrocyclic lrrk2 kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20200917 |